跳至主要内容
临床试验/NCT05314868
NCT05314868终止不适用

Postmarket, Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium Used as a Patch in Cardiac Repair or Reconstruction Surgery

Artivion Inc.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2022年3月31日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
Artivion Inc.
入组人数
10
试验地点
1
主要终点
Overall survival

研究概览

简要总结

The objective of this postmarket, retrospective, single center study is to evaluate the clinical outcomes of patients who have received PhotoFix® Decellularized Bovine Pericardium (PhotoFix) as a patch within a cardiac surgical repair or reconstruction procedure. PhotoFix is prepared from bovine pericardium, which is stabilized using a dye-mediated photo-oxidation process and sterilized using aseptic processing techniques.

详细描述

This study will include a review of approximately 300 charts spanning the implant period of January 1, 2018 through June 30, 2019. Those that meet the inclusion and exclusion criteria will undergo full review and data extraction to be captured in the electronic database. Given the retrospective nature of the study design, a Waiver of Consent will be requested from the Institutional Review Board (IRB). Potential subjects this study are pediatrics or adults who underwent cardiac repair surgery that necessitated the use of a patch. Targeted cardiac procedures include intracardiac repair (including annulus and septal repair), great vessel repair (including superior vena cava, inferior vena cava, pulmonary arteries, pulmonary veins, and ascending aorta), and suture line buttressing and pericardial closure. Follow-up data will be abstracted from the subject's medical record. Study specific testing, including imaging and laboratory testing, will not be required.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Subject has undergone a cardiac procedure which falls within the indications for use and required the use of PhotoFix Decellularized Bovine Pericardium

排除标准

  • Subject required valve leaflet repair using PhotoFix

结局指标

主要结局

Overall survival

时间窗: Up to 5 years

Mortality

次要结局

  • All-cause reoperation(Up to 5 years)
  • Morbidity(Up to 5 years)
  • Explant(Up to 5 years)
  • Device-related reoperation(Up to 5 years)

研究者

发起方
Artivion Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验